Panacea Biotec , a leading biotechnology company, has made a significant move in the Indian baby care market with the launch of two new product lines through its wholly-owned subsidiary, Panacea Biotec Pharma Limited (PBPL). The company has introduced 'NikoMom', touted as India's first 100% toxin-free baby care line, and 'Staart Prime', an infant milk substitute.

NikoMom: A New Era in Baby Skin Care

NikoMom represents a breakthrough in the baby care segment, offering a range of products designed with safety and purity at their core. The line includes:

• Baby Massage Oil
• Baby Head to Toe Wash
• Baby Daily Lotion
• Diaper Rash Cream

These products are developed using advanced technologies to cater to specific baby care needs:

• The Baby Massage Oil features 'Hydranest Technology' for muscle and bone strengthening, deep skin hydration, and enhanced skin elasticity.
• The Head to Toe Wash employs 'TenderNest Technology' for gentle cleansing while preserving skin moisture and natural oils.
• The Daily Lotion utilizes 'DermaNest Technology' for 24-hour hydration and strengthening of the skin's moisture barrier.
• The Diaper Rash Cream incorporates 'HealNest Technology' to boost cellular skin repair and prevent rash triggers.

Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec Ltd., emphasized the company's commitment to baby care, stating, "NikoMom stands for purity, safety, and innovation, ensuring that every child receives the gentlest care without toxic chemicals."

Staart Prime: Addressing Infant Nutrition

Alongside NikoMom, Panacea Biotec has launched 'Staart Prime', an infant milk substitute product. The range includes formulations for different stages of infant development:

• Staart Prime Stage 1
• Staart Prime Stages 2-3-4

Both NikoMom and Staart Prime are currently focused on the domestic Indian market, with potential international launches planned for the future.

Market Strategy and Availability

The new products will be available through various channels:

• 7NShop.com, Panacea Biotec's official e-commerce platform
• Online retailers such as Amazon, Flipkart, and Tata 1mg
• Local retailers across India

This launch aligns with Panacea Biotec's broader strategy of expanding its consumer healthcare portfolio under the '7N Panacea Biotec' brand, which focuses on science-driven, everyday healthcare solutions for families.

Company Background

Panacea Biotec has a strong presence in the biotechnology sector, with established capabilities in vaccines, pharmaceuticals, and nutrition. The company has played a significant role in polio eradication efforts, having supplied over 10 billion doses of polio vaccine in India and other developing countries.

With this latest launch, Panacea Biotec aims to leverage its expertise in healthcare to address the growing demand for safe, high-quality baby care products and infant nutrition in the Indian market.

Panacea Biotec , a leading biotechnology company, has reported a significant turnaround in its financial performance for the first quarter. The company's consolidated net profit stood at ₹41.00 crore, marking a substantial improvement from a loss of ₹158.00 crore in the same period last year.

Revenue Growth

The company's quarterly revenue witnessed a robust increase of 44%, rising to ₹1,667.00 crore from ₹1,157.00 crore year-over-year. This surge in revenue reflects a strong demand for Panacea Biotec's products and services.

Profitability Improvement

Panacea Biotec's profitability saw a notable enhancement, with the loss before tax narrowing to ₹48.00 crore compared to a loss of ₹198.00 crore in the previous year. This improvement indicates the company's efforts in cost management and operational efficiency.

Exceptional Item

During the quarter, Panacea Biotec recorded an exceptional item of ₹113.00 crore. This exceptional income includes:

1. ₹85.80 crore from a settlement agreement with Apotex Inc., USA, resolving an ongoing dispute.
2. ₹27.40 crore from the sale of domestic pharmaceutical brands of Panacea Biotec Pharma Limited (PBPL).

Segment Performance

The company's financial results show a mixed performance across its two main segments:

1. Vaccines: This segment reported revenue of ₹1,122.50 crore but incurred a loss of ₹42.50 crore before tax.
2. Formulations: The formulations segment generated revenue of ₹544.50 crore and reported a profit before tax of ₹108.10 crore.

Balance Sheet and Capital

As of June 30, Panacea Biotec's balance sheet reflects:

Future Outlook

The management's commentary suggests a positive outlook. The company has strengthened its working capital position and is pursuing growth opportunities, including:

• Setting up new facilities to enhance vaccine drug substance manufacturing capacities
• Scaling up its nutrition and pharmaceutical formulations business
• Securing higher long-term business orders for vaccines from key institutional customers

These strategic initiatives, coupled with the company's improved financial performance, indicate Panacea Biotec's focus on sustainable growth and profitability in the coming quarters.

Note: All figures are in Indian Rupees (INR) and have been converted to crore for clarity.